Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Poniatowa – page 57

827 clinical trials in Poniatowa, Poland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Poniatowa at a glance
827
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

827 trials in Poniatowa

Open in trial search

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Gastrooesophageal cancer+5

Not recruiting

Study of Nivolumab or Placebo for Patients with Removed Esophageal or Gastroesophageal Junction Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Chronic lymphocytic leukaemia+1

Not recruiting

Study Comparing Acalabrutinib and Venetoclax with Venetoclax and Obinutuzumab for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

Asthma

Not recruiting

Study on the Effectiveness and Safety of Fluticasone Propionate and Salbutamol Sulfate for Patients with Asthma

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Hormone receptor positive breast cancer

Not recruiting

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Diffuse large B-cell lymphoma recurrent

Not recruiting

Study of Mosunetuzumab and Polatuzumab Vedotin for Patients with Diffuse Large B-Cell Lymphoma After Initial Treatment or in Elderly/Unfit Untreated Patients

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Mosunetuzumab
  • Sponsor:F. Hoffmann-La Roche AG

Follicular lymphoma

Not recruiting

Study of Zanubrutinib and Obinutuzumab for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Beigene Ltd.

Renal cell carcinoma+1

Not recruiting

Study of Axitinib and Immune Checkpoint Inhibitors for Patients with Untreated Advanced or Metastatic Kidney Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Heart failure with preserved ejection fraction

Not recruiting

Study on the Safety and Tolerability of BMS-986435 in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986435
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Rheumatoid arthritis

Not recruiting

Study on Burfiralimab for Patients with Moderate to Severe Rheumatoid Arthritis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Burfiralimab
  • Sponsor:Immunemed Inc.

Neoplasm malignant

Not recruiting

Study of AFM24 and Atezolizumab for Patients with Advanced or Metastatic EGFR-expressing Cancers

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AFM24
  • Sponsor:Affimed GmbH

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Poniatowa

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical trials focusing on hyperlipidemia management, specifically targeting patients at high and very high cardiovascular risk. The research evaluates the effectiveness of rosuvastatin treatments and combination therapies in achieving optimal LDL-C reduction.

  • Lipid Management
  • Cardiovascular Risk Prevention
  • Combination Therapy Assessment

These studies aim to establish more effective treatment protocols for patients requiring intensive lipid-lowering therapy.

02 Rheumatology Studies

Comprehensive research evaluating biosimilar treatments for rheumatoid arthritis. The trials compare the efficacy of new biosimilar options with established treatments, focusing on patients with moderate to severe disease conditions.

  • Biosimilar Development
  • Treatment Efficacy Assessment
  • Immunogenicity Studies

This research aims to expand treatment options while maintaining high efficacy standards in rheumatoid arthritis management.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.